LAHORE: Power over healthcare decisions is gradually shifting from physicians to patients. Armed with digital tools, wearable devices, online medical literature and real-time monitoring systems, patients are becoming informed, self-directive and increasingly influential in determining their own treatment pathways.
Pakistan has a vibrant pharma industry. In 12 months ending in March 2025 its retail sales passed the Rs1 trillion milestone. Pakistan’s pharmaceutical companies now command 75 per cent of market share by value approximately producing 2.9 billion to 3 billion units against around 900 million units sold by multinationals.
Digital disruption has now begun reshaping the pharmaceutical industry worldwide. The most profound change is not technological alone; it is structural. Pakistan will not remain insulated from this transformation. The speed at which digital innovations now travel ensures that emerging economies can no longer rely on delayed adoption. Unlike the past, when new medical paradigms took decades to arrive, digital health solutions cross borders almost instantly.
Traditionally, pharmaceutical sales particularly in Pakistan — have been physician-centric. Marketing strategies focused overwhelmingly on influencing prescribing doctors through medical representatives, conferences and sampling. However, this model is steadily weakening. Even today, a segment of Pakistan’s literate urban patients walks into clinics armed with information gathered online, from diagnostic apps, health forums and wearable monitoring devices. While the country’s overall digital health literacy remains low, the direction of change is unmistakable.
Globally, pharmaceutical companies are already adapting. Several leading firms have developed “digital medicines” embedded with microchips that activate once the patient consumes the pill. These chips transmit data to a wearable patch attached to the body, which records not only medication adherence but also physiological indicators such as heart rate, activity levels and, in some cases, blood pressure. The information is relayed via smartphone applications to healthcare providers, enabling real-time monitoring of treatment outcomes.
This development fundamentally alters the doctor-patient relationship. Patients can now be monitored remotely, reducing the need for frequent hospital visits and enabling early intervention when health indicators deviate from expected norms.
In the digital era, drugmakers can no longer remain mere manufacturers of molecules. They must evolve into providers of integrated therapeutic solutions. This requires deep partnerships — not only with technology firms but also, increasingly, with other pharmaceutical companies.
The future patient will demand convenience, integration and outcomes rather than isolated products. As patients become more informed, they will prefer bundled therapeutic solutions — combinations of drugs, diagnostics and digital monitoring tools — offered through a single platform. Such integration reduces treatment complexity and improves compliance. This collaborative model has already gained traction in oncology, where leading firms combine novel immunotherapies, targeted treatments and companion diagnostics to deliver personalized cancer care.
At present, Pakistan’s pharmaceutical sector remains largely traditional. Most local manufacturers focus on generics, price competition and volume-driven sales. Digital investment is minimal, limited mostly to basic marketing automation and supply-chain tracking. Regulatory frameworks have yet to evolve to accommodate digital therapeutics, remote monitoring devices or data-driven treatment models. Moreover, healthcare infrastructure — particularly in rural areas — lacks the digital connectivity required for widespread adoption.
Pakistan also possesses latent strengths as smartphone penetration has risen rapidly, mobile broadband coverage is expanding, and telemedicine platforms gained visibility during the Covid-19 pandemic. Younger physicians are increasingly comfortable with digital tools, while private hospitals are experimenting with electronic medical records and remote consultations. These developments suggest that the foundations, though weak, are forming.
The greatest risk for Pakistani pharmaceutical companies lies in complacency. If they fail to adapt, global players, or even regional digital health platforms, could bypass them entirely by offering integrated solutions directly to patients and providers. In such a scenario, local firms would be relegated to low-margin contract manufacturing, losing both relevance and pricing power.
Digital disruption is not a distant threat; it is an unfolding reality. The question is not whether Pakistan’s pharmaceutical industry will be affected, but whether it will participate as a proactive innovator or remain a passive follower in a patient-led healthcare future.
